妊娠期糖尿病的药物治疗:观点与反观点
本文以观点与反观点形式引用美国妇产科医师学会实践简报和美国糖尿病学会诊疗标准立场并予以讨论,综述妊娠期糖尿病药物治疗的相关证据,涉及药物是否通过胎盘、证据质量、血糖控制作为主要结局的依据及二甲双胍、格列本脲或胰岛素对次要结局的效果。
要点
- 本文以观点与反观点形式讨论妊娠期糖尿病药物治疗的争议。
- 讨论涉及药物是否通过胎盘、证据质量、主要结局选择及次要结局效果。
- 作者认为一种药物适合所有患者(胰岛素、格列本脲或二甲双胍)是谬误。
核心结论
- 一种药物适合所有患者(无论是胰岛素、格列本脲还是二甲双胍)是谬误。
- 不同药物提供某些获益,但并非所有获益,也并非对所有患者。
研究设计与样本
- 本文为综述,引用美国妇产科医师学会实践简报和美国糖尿病学会诊疗标准立场并讨论相关证据。
主要发现
- 主要议题包括哪些降糖药通过胎盘、证据质量与数据来源有效性、将血糖控制设为主要结局的理由及哪种药物(二甲双胍、格列本脲或胰岛素)对次要结局最有效。
- 文中还涉及妊娠期糖尿病管理决策路径的步骤以及胰岛素、格列本脲或二甲双胍使用的当前成本。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Controversies persist over the most efficacious pharmacologic treatment for gestational diabetes mellitus. For purposes of accuracy in this article, the individual American College of Obstetricians and Gynecologists Practice Bulletin and American Diabetes Association Standards of Medical Care positions on each issue are quoted and then deliberated with evidence of counter claims presented in point/counterpoint. This is a review of all the relevant evidence for the most holistic picture possible. The main issues are (1) which diabetic drugs cross the placenta, (2) the quality of evidence and data source validity, (3) the rationale for the designation of glucose control as the primary outcome in gestational diabetes mellitus, and (4) which drugs (metformin, glyburide, or insulin) are most effective in improving secondary outcomes. The concept that 1 drug fits all, whether it be insulin, glyburide, or metformin, is a fallacy. Different drugs provide certain benefits but not all the benefits and not to all patients. In addition, the steps in the gestational diabetes mellitus management decision path and the current cost of the use of insulin, glyburide, or metformin are addressed. In the future, we must consider studying the potential of diabetic drugs that currently are used in nonpregnancy and incorporating the concept of precision medicine in the decision tree to maximize pregnancy outcomes.
引用
- Langer O. Pharmacological treatment of gestational diabetes mellitus: point/counterpoint. Am J Obstet Gynecol. 2018. PMID: 29499921. doi:10.1016/j.ajog.2018.01.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。